Roche Q1 Sales Up 10%, Confirms 2022 Outlook
By Ludwig Burger (Reuters) -Swiss drugmaker Roche’s first quarter sales rose a better-than-expected 10% on strong U.S. demand for rapid COVID-19 antigen tests and drugs including Ocrevus against multiple sclerosis as well as Hemlibra against haemophilia. Quarterly sales rose to 16.44 billion Swiss francs ($17.17 billion), up from 14.93 billion Swiss francs in the year-earlier…
